Clinical Trial for Patients With Previously Treated Recurrent or Metastatic Cervical Cancer Is ...

Retrieved on: 2022-03-19 21:06:29

Tags for this article:

Clinical medicine

Drugs

Medicine

Orphan drugs

Clusters of differentiation

Immune system

Cancer immunotherapy

Breakthrough therapy

Programmed cell death protein 1

Response evaluation criteria in solid tumors

PD-L1

Tislelizumab

Click the tags to see associated articles and topics

Clinical Trial for Patients With Previously Treated Recurrent or Metastatic Cervical Cancer Is .... View article details on HISWAI: https://www.cancernetwork.com/view/clinical-trial-for-patients-with-previously-treated-recurrent-or-metastatic-cervical-cancer-exploring-ociperlimab-plus-tislelizumab-combo

Excerpt

Ociperlimab is a humanized monoclonal antibody that binds to TIGIT, ... Patients who have had prior treatment with any PD-1/PD-L1 antibodies, ...

Article found on: www.cancernetwork.com

View Original Article